Frequently Asked Questions

How do you balance between opportunity and risk in China?

By turning it into a quantified decision rather than a judgment call. The variables that matter, NMPA approval timeline, NRDL pricing exposure, provincial procurement dynamics, and reference pricing spillover, are all modelable. SILREAL structures these into a go/no-go framework that gives boards a defensible investment decision, not a market overview.

How does a China NRDL price concession affect our U.S. valuation or licensing deal terms?

Directly. The 2025 MFN executive order benchmarks U.S. prices against the lowest price in a basket of OECD comparator countries. If your NRDL price undercuts net prices in France, Germany, or the UK, those basket countries face downward pressure, which compresses the MFN benchmark. A 5 to 10% U.S. pricing compression on an asset where the U.S. represents 60% of global peak sales is a material valuation gap that needs to be in your deal model before you sit down with a counterparty. SILREAL builds that sensitivity in before negotiations begin.

We are evaluating a Chinese biotech asset for in-licensing. What due diligence does the European regulatory pathway require that standard BD processes miss?

Three gaps reprice deals late most often: EMA data transferability from NMPA-only clinical packages, bridging study requirements for China-only trial designs, and EU JCA implications that make HTA outcomes in one major European market cascade across others. SILREAL identifies and quantifies these gaps before term sheets are signed.

When in our development timeline should we engage China, and what does getting the sequencing wrong cost us?

Engaging too early risks establishing a low public reference price before your asset has full global differentiation. Engaging too late means competitors hold the NRDL slot and hospital formulary positions. The right answer is asset-specific. SILREAL runs a dual-scenario sequencing assessment during Phase II to III so the timing decision is evidence-based before it becomes expensive to reverse.

What does the NMPA approval process actually require for a foreign-manufactured drug, and where do foreign applicants most commonly lose time?

Delays concentrate in three areas: clinical data packages that do not meet NMPA local population requirements, eCTD dossier gaps now mandatory from March 2026, and post-approval change management tightened under the revised Drug Administration Law effective May 2026. Treating an NMPA submission as a straightforward translation of an EMA or FDA dossier is the most common and costly mistake foreign applicants make. SILREAL runs a regulatory gap analysis before submission, not after rejection.

How should we structure a licensing deal with a Chinese biotech to protect against cross-market pricing risk?

Standard royalty and milestone structures do not distribute pricing downside across markets. The mechanics that do include milestones tied to reimbursement outcomes rather than approval alone, revenue-share adjustments linked to realized net pricing, and earn-outs against peak sales across defined geographies. SILREAL drafts these terms with both China pricing dynamics and European deal context built in from the outset.

What policy signals tell us a new NRDL negotiation window is opening, and how much lead time do we realistically have?

Typically three to nine months, if the right signals are being monitored: NHSA guidance on upcoming reform cycles, category-specific inclusion rounds, and provincial procurement or DRG pilots that tend to precede national reimbursement. That window aligns closely with the time needed to strengthen a pharmacoeconomic dossier and align internal stakeholders. SILREAL monitors these signals on a continuous basis and converts them into client-specific timing recommendations.

Our asset has strong EU data but no China clinical data. Can we still pursue NMPA approval and NRDL listing competitively?

Approval is achievable. The 2019 Drug Administration Law reforms enable NMPA review on foreign clinical data for innovative therapies with clear unmet need and no local comparator. Competitive NRDL positioning is a separate question. Negotiation leverage is materially stronger with local real-world data or a China subpopulation analysis, even where approval was granted without it. SILREAL assesses whether bridging evidence is required or commercially advantageous and integrates that into the overall market entry timeline.

Why should we prioritize China at all given the regulatory and pricing complexity?

Because the competitive activity is already well underway. In H1 2025, China accounted for 44.5% of global pharma licensing deal value. NRDL slots, hospital formulary positions, and local partnership networks are being secured now by companies that made the decision to engage. Organizations that delay do not avoid the complexity; they face it later from a weaker commercial position. SILREAL helps clients enter at the right moment with the right structure in place.

What does a first engagement with SILREAL actually look like?

A scoped six-week mandate with a defined deliverable: a regulatory pathway and market entry assessment, an NRDL scenario model integrated with your global valuation assumptions, or a China BD asset shortlist for in-licensing. The output is board-ready, whether that is a go/no-go recommendation, a deal structure, or a prioritized asset list. This is not a retainer arrangement or a research subscription. The right starting point is a thirty-minute scoping call to define the specific question your team needs answered.